Genmab — Oktober 2017
-
REVLIMID
sales for the third quarter increased 10 percent to $2,081 million. Sales growth was driven primarily by increased volume, as a result of increases in duration and market share. U.S. sales of $1,361 million and international sales of $720 million increased 18 percent and decreased 2 percent year-over-year, respectively. -
POMALYST
/IMNOVID sales for the third quarter were $417 million, an increase of 22 percent year-over-year. U.S. sales were $268 million and international sales were $149 million, an increase of 32 percent and 8 percent year-over-year, respectively. POMALYST/IMNOVID sales growth was driven primarily by increased volume as a result of increases in market share and duration. -
Celgene is down 15% in premarket!
-
Celgene is down 31% since 2nd October!
-
...det kan ikke rigtigt betale sig at skuffe forventningerne... Auch!
-
IBB on TL support , will it hold? https://twitter.com/EgidiusLambrech/status/923544976822239234
-
it seems that FY revlimid guidance remains unchanged at 8b-8,3b. Remarkable considering the 20% price hike....
-
Kunne godt tænke mig, at vi satte lidt fokus på analytikernes rolle og funktion. Tænker de ofte vurderer tingene "forkert", og så skuffes markedet, når de reelle tal kommer. Tillægges analytikernes vurderinger, og dermed dagskursen, en for høj vægt i f.h.t virkelighedens virkelighed?
-
bankanalytikerne har da været mere forsigtige end prognoser her på chatten!
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind